Drugs / QLP2117
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05830045 | May 2023 → Apr 2025 | cancer | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06911827 | May 2025 → Dec 2027 expected | neoplasm | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-12-15 | Qilu Pharmaceutical Co., Ltd. | Results 凤凰网丨齐鲁制药两款抗肿瘤创新药最新临床数据亮相ESMO亚洲年会 qilu-pharma.com ↗
疗效方面，客观缓解率（ORR）和疾病控制率（DCR）分别为13.0%和 52.2%。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-12-15 | Qilu Pharmaceutical Co., Ltd. | 凤凰网丨齐鲁制药两款抗肿瘤创新药最新临床数据亮相ESMO亚洲年会 qilu-pharma.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLP2117 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05830045 ↗ |